PDB13 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES

Value in Health ◽

10.1016/s1098-3015(10)63283-4 ◽

2006 ◽

Vol 9 (6) ◽

pp. A227-A228

Author(s):

P McEwan ◽

AP Tetlow ◽

P Holmes ◽

CD Poole ◽

CJ Currie

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Relative Cost ◽

Nph Insulin ◽

Relative Cost Effectiveness ◽

Download Full-text

ED4 THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA

Value in Health ◽

10.1016/s1098-3015(10)64861-9 ◽

2007 ◽

Vol 10 (6) ◽

pp. A223 ◽

Author(s):

P McEwan ◽

N Mehin ◽

AP Tetlow ◽

P Sharplin

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Real Life ◽

Relative Cost ◽

Nph Insulin ◽

Relative Cost Effectiveness ◽

Life Data ◽

Download Full-text

PDB7 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 1 DIABETES

Value in Health ◽

10.1016/s1098-3015(10)63277-9 ◽

2006 ◽

Vol 9 (6) ◽

pp. A225-A226

Author(s):

P McEwan ◽

CD Poole ◽

P Holmes ◽

AP Tetlow ◽

CJ Currie

Keyword(s):

Type 1 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Relative Cost ◽

Nph Insulin ◽

Relative Cost Effectiveness ◽

Download Full-text

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

Current Medical Research and Opinion ◽

10.1185/030079907x167570 ◽

2007 ◽

Vol 23 (sup1) ◽

pp. S21-S31 ◽

Author(s):

Phil McEwan ◽

Chris D. Poole ◽

Tony Tetlow ◽

Paul Holmes ◽

Craig J. Currie

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Nph Insulin ◽

The Uk ◽

Download Full-text

PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK

Value in Health ◽

10.1016/j.jval.2018.09.776 ◽

2018 ◽

Vol 21 ◽

pp. S130

Author(s):

S. Webster ◽

N. Hau ◽

A.V. Ustyugova ◽

A.R. Kansal ◽

O. Reifsnider

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Cost Effectiveness ◽

Relative Cost ◽

Relative Cost Effectiveness ◽

The Uk ◽

Diabetes Patients

Download Full-text

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp45203 ◽

2007 ◽

Vol 45 (04) ◽

pp. 203-221 ◽

Author(s):

M. Brändle ◽

M. Azoulay ◽

R.-A. Greiner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Cost Utility ◽

Download Full-text

The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting

Diabetes Obesity and Metabolism ◽

10.1111/dom.13375 ◽

2018 ◽

Vol 20 (10) ◽

pp. 2371-2378 ◽

Author(s):

Russell Drummond ◽

Samuel Malkin ◽

Michelle Du Preez ◽

Xin Ying Lee ◽

Barnaby Hunt

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Fixed Ratio ◽

Insulin Degludec ◽

Effectiveness Analysis ◽

The Uk ◽

Download Full-text

PDB18 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Value in Health ◽

10.1016/s1098-3015(10)68735-9 ◽

2007 ◽

Vol 10 (3) ◽

pp. A64-A65

Author(s):

P McEwan ◽

N Mehin ◽

AP Tetlow ◽

P Sharplin

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Real Life ◽

Relative Cost ◽

Nph Insulin ◽

Life Data ◽

Download Full-text

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes Obesity and Metabolism ◽

10.1111/dom.12250 ◽

2014 ◽

Vol 16 (4) ◽

pp. 366-375 ◽

Author(s):

M. Evans ◽

M. Wolden ◽

J. Gundgaard ◽

B. Chubb ◽

T. Christensen

Keyword(s):

Type 2 Diabetes ◽

Health Care ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Basal Insulin ◽

Health Care Cost ◽

Insulin Degludec ◽

Download Full-text

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-019-0180-9 ◽

2019 ◽

Vol 17 (1) ◽

Author(s):

E. Lau ◽

A. Salem ◽

J. C. N. Chan ◽

W. Y. So ◽

A. Kong ◽

...

Keyword(s):

Type 2 Diabetes ◽

Hong Kong ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Cost Effectiveness Analysis ◽

Nph Insulin ◽

Effectiveness Analysis ◽

Neutral Protamine Hagedorn

Download Full-text

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Current Medical Research and Opinion ◽

10.1185/030079906x00000 ◽

2006 ◽

Vol 22 (5) ◽

pp. 967-969 ◽

Author(s):

Craig J. Currie ◽

Phil McEwan ◽

Chris Poole ◽

William J. Valentine ◽

Andrew J. Palmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

Biphasic Insulin Aspart 30 ◽

The Uk ◽

Download Full-text